HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) All Versions of this Article: 0091270007304780v1 47/10/1327    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Bifano, M. Articles by LaCreta, F. Search for Related Content PubMed PubMed Citation Articles by Bifano, M. Articles by LaCreta, F. Social Bookmarking                         What's this?

Absence of a Pharmacokinetic Interaction Between Entecavir and Adefovir

From Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey (Mr Bifano, Dr Smith, Dr Zhang, Dr Grasela, Dr LaCreta); and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (Dr Yan).

This study evaluated the effect of entecavir on the pharmacokinetics of adefovir and the effect of adefovir on the pharmacokinetics of entecavir using a fixed-sequence crossover design in healthy adult subjects. Subjects received 10 mg of adefovir once daily on days 1 to 4, 1 mg of entecavir on days 5 to 14, and 1 mg of entecavir plus 10 mg of adefovir on days 15 to 24. Pharmacokinetic assessments were performed on days 4 and 24 for adefovir and on days 14 and 24 for entecavir. The geometric mean ratios (90% confidence interval) for area under the plasma concentration-time curve in 1 dosing interval, peak plasma concentration, and 24-hour postdose plasma concentration of entecavir when coadministered with adefovir and of adefovir when coadministered with entecavir were within the prespecified 0.80 to 1.25 no-effect range. Entecavir and adefovir were well tolerated when administered in combination. Therefore, the pharmacokinetic data generated in this study indicate that entecavir and adefovir can be coadministered without the need for dosage adjustment.

Key Words: Entecavir • adefovir • pharmacokinetics • drug interactions • hepatitis B virus

Address for correspondence: Marc Bifano, MS, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?